Indivior PLC Reports Exit/Disposal Costs
Ticker: INDV · Form: 8-K · Filed: Aug 26, 2025 · CIK: 1625297
Sentiment: neutral
Topics: restructuring, disposal, corporate-action
TL;DR
Indivior PLC filed an 8-K on Aug 26, 2025, about exit/disposal costs. Details TBD.
AI Summary
On August 26, 2025, Indivior PLC filed an 8-K report detailing costs associated with exit or disposal activities. The filing does not specify the exact nature or financial impact of these activities, but it indicates a formal reporting of such events.
Why It Matters
This filing signals potential restructuring or divestment activities within Indivior PLC, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The filing indicates potential restructuring or disposal activities, which inherently carry financial and operational risks.
Key Players & Entities
- Indivior PLC (company) — Registrant
- August 26, 2025 (date) — Date of earliest event reported
FAQ
What specific activities are associated with the exit or disposal costs reported by Indivior PLC?
The provided filing (8-K dated August 26, 2025) does not specify the nature of the exit or disposal activities, only that costs are associated with them.
What is the total financial amount of the costs associated with exit or disposal activities?
The filing does not disclose a specific dollar amount for the costs associated with exit or disposal activities.
When did the exit or disposal activities commence or become reportable?
The filing is dated August 26, 2025, and reports on events as of that date, indicating the activities are current or have recently occurred.
Is this filing related to a specific product line or geographical region?
The filing does not provide details on whether the exit or disposal activities are tied to a specific product line or region.
What is the primary business of Indivior PLC?
Indivior PLC is primarily involved in the Pharmaceutical Preparations industry, as indicated by its SIC code [2834].
Filing Stats: 1,077 words · 4 min read · ~4 pages · Grade level 14.9 · Accepted 2025-08-26 07:45:34
Key Financial Figures
- $0.50 — on which registered Ordinary shares, $0.50 nominal value per share INDV The Nasdaq
- $16 — employee exit charges of approximately $16 to $19 million, the majority of which w
- $19 m — ee exit charges of approximately $16 to $19 million, the majority of which will be re
- $15 — non-cash asset charges of approximately $15 to $22 million in the third quarter of
- $22 million — h asset charges of approximately $15 to $22 million in the third quarter of 2025 resulting
- $8 — tax planning expenses of approximately $8 to $9 million, which will be recognized
- $9 m — lanning expenses of approximately $8 to $9 million, which will be recognized in the
- $39 — s to recognize a total of approximately $39 to $50 million of restructuring charges
- $50 million — cognize a total of approximately $39 to $50 million of restructuring charges pre-tax, of wh
- $27 — restructuring charges pre-tax, of which $27-$35 million will be cash, and which are
- $35 million — ructuring charges pre-tax, of which $27-$35 million will be cash, and which are expected to
Filing Documents
- indv-20250826.htm (8-K) — 32KB
- 0001625297-25-000059.txt ( ) — 140KB
- indv-20250826.xsd (EX-101.SCH) — 2KB
- indv-20250826_lab.xml (EX-101.LAB) — 21KB
- indv-20250826_pre.xml (EX-101.PRE) — 12KB
- indv-20250826_htm.xml (XML) — 2KB
05 Costs Associated with Exit or Disposal Activities
Item 2.05 Costs Associated with Exit or Disposal Activities. The current management team of Indivior PLC ("Indivior" or the "Company"), with the oversight of the Company's Board of Directors, approved an enterprise-wide initiative – the Indivior Action Agenda – that started in the second quarter of 2025. The Indivior Action Agenda, as disclosed on July 31 st , is a three-phased, multi-year operational roadmap intended to maximize the potential of Indivior's business and make a positive difference in the lives of people living with opioid use disorder ("OUD") while creating value for shareholders. The Indivior Action Agenda contemplates that management, under the supervision of the Company's Board of Directors, will develop and propose for approval and adoption, specific plans to execute that agenda. Phase 1 of the Indivior Action Agenda – Generate Momentum – is being implemented through the end of 2025 with a focus on the following key areas: Growing SUBLOCADE in the U.S. through the remainder of 2025 by improving commercial execution; Taking actions to simplify the organization by eliminating all non-essential activities; and, Determining the actions and investments necessary to accelerate long-acting injectable (LAI) penetration in the U.S. and to accelerate SUBLOCADE net revenue growth in 2026 and beyond. On August 26, 2025, the Company adopted one of the first major initiatives designed to execute on Phase 1 the Indivior Action Agenda - today, the Company began taking actions on that initiative, which are designed to simplify the organization and drive transparency and accountability through the elimination of non-essential activities. These actions are expected to generate operational momentum and consist of: Headcount Reductions: The Company expects pre-tax employee severance and related employee exit charges of approximately $16 to $19 million, the majority of which will be recognized in the third quarter of 2025. Real Estate Consolidations: The Compa
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Indivior PLC Date: August 26, 2025 By: /s/ Ryan Preblick Name: Ryan Preblick Title: Chief Financial Officer